OCUL - Ocular Pharma Total Debt to Capital

The total debt-to-equity ratio for Ocular Therapeutix (OCUL) stands at 0.14, which is significant amid a deep overhaul of the development portfolio and a shift away from mergers in favor of investment alliances. Business profitability is based on the commercialization of certified vision care products and the outcomes of Axpaxli tests. The company's stability relies on insurance reimbursement, capital expenditure rates, and the stability of component logistics.

While modest current sales do not yet cover the development costs of new hydrogel implants, monitoring funding sources becomes critical for Ocular Therapeutix (OCUL). This ratio compares total liabilities to equity, measuring the proportion of borrowed funds within the asset structure to assess financial stability. An increase in this value signals accumulating risks, which is clearly reflected in the financing structure chart (debt-to-equity).